This press release contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. There are significant risks and uncertainties in pharmaceutical research and development. There can be no guarantees with respect to pipeline products that the products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. The company's results may also be affected by such factors as competitive developments affecting current products; rate of sales growth of recently launched products; the timing of anticipated regulatory approvals and launches of new products; other regulatory developments and government investigations; patent disputes and other litigation involving current and future products; the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals; changes in tax law; asset impairments and restructuring charges and the impact of exchange rates. For additional information about the factors that affect the company's business, please see the company's latest Form 10-K, filed March 2008, and Form 10-Q filed November 2008. The company undertakes no duty to update forward-looking statements.
Alimta(R) (pemetrexed, Lilly) Byetta(R) (exenatide injection, Amylin Pharmaceuticals) Cialis(R) (tadalafil, Lilly) Comfortis(TM) (Lilly) Cymbalta(R) (duloxetine hydrochloride, Lilly) Erbitux(R) (cetuximab, ImClone Systems, Lilly) Gemzar(R) (gemcitabine hydrochloride, Lilly) Humalog(R) (insulin lis
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved